What is Turn Therapeutics?
Turn Therapeutics operates as a concept-to-approval research and development organization dedicated to creating best-in-class products for critical healthcare areas including infection control, skin disease, and wound care. The company leverages proprietary technologies that are currently employed by leading healthcare institutions for the daily management of a wide spectrum of skin and wound conditions. Its focus on innovative solutions positions it as a key player in advancing patient care within these specialized medical fields.
How much funding has Turn Therapeutics raised?
Turn Therapeutics has raised a total of $100M across 2 funding rounds:
Other Financing Round
$75M
Debt
$25M
Other Financing Round (2024): $75M with participation from Global Emerging Markets
Debt (2026): $25M led by Avenue Capital Group
Key Investors in Turn Therapeutics
Global Emerging Markets
Global Emerging Markets (GEM) is a $3.4 billion alternative investment group that specializes in managing a diverse array of investment vehicles focused on emerging markets worldwide. The firm offers a range of investment options, including small-mid cap management buyouts, private investments in public equities, and select venture investments.
Avenue Capital Group
Founded in 1995, Avenue Capital Group is an American multinational investment firm focusing on distressed securities and private equity. Avenue Capital Group is located in New York.
What's next for Turn Therapeutics?
With the recent influx of major strategic investment and significant enterprise-level backing, Turn Therapeutics is poised for an accelerated phase of development and commercialization. The company's focus on novel technologies for infection control and wound care suggests a strategic expansion into markets demanding advanced therapeutic solutions. Future endeavors will likely involve scaling production, expanding clinical trials, and forging deeper partnerships within the healthcare ecosystem to bring its innovative products to a broader patient base. This capital infusion is a clear indicator of the company's potential to significantly impact its target markets.
See full Turn Therapeutics company page
